ストックスクリーナーアプリを入手
45.90
1.84%
-0.86
アフターアワーズ：
45.91
0.010
+0.02%
前日終値:
$46.76
開ける：
$47.15
24時間の取引高:
841.13K
Relative Volume:
1.44
時価総額：
$2.70B
収益：
$45.48M
当期純損益:
$162.11M
株価収益率:
-17.13
EPS:
-2.68
ネットキャッシュフロー:
$-64.16M
1週間 パフォーマンス:
-5.22%
1か月 パフォーマンス:
+3.45%
6か月 パフォーマンス:
+75.93%
1年 パフォーマンス:
+175.68%
1日の値動き範囲:
$43.86
$47.31
1週間の範囲:
$43.86
$48.30
52週間の値動き範囲:
$14.78
$48.89
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
名前
Protagonist Therapeutics Inc
セクター
電話
(510) 474-0170
住所
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-05-25 | 再開されました | Jefferies | Buy |
| 2022-08-25 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-02-11 | 開始されました | BTIG Research | Buy |
| 2021-10-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-10-11 | アップグレード | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-05-24 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-05-24 | 開始されました | Northland Capital | Outperform |
| 2021-01-06 | 開始されました | JP Morgan | Overweight |
| 2020-12-16 | 開始されました | Piper Sandler | Overweight |
| 2020-09-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-15 | 開始されました | Jefferies | Buy |
| 2020-05-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-07-08 | 開始されました | H.C. Wainwright | Buy |
| 2019-05-09 | アップグレード | Stifel | Hold → Buy |
| 2018-12-06 | 開始されました | Nomura | Buy |
| 2018-01-29 | 開始されました | Stifel | Buy |
| 2017-07-21 | 開始されました | BTIG Research | Buy |
すべてを表示
Protagonist Therapeutics Inc (PTGX) 最新ニュース
Protagonist Therapeutics (NASDAQ:PTGX) Shares Down 5.4%Here's What Happened - MarketBeat
Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting - Corsicana Daily Sun
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Acquired by Mirae Asset Global Investments Co. Ltd. - Defense World
Vanguard Group Inc's Strategic Acquisition in Protagonist Therap - GuruFocus.com
Protagonist Therapeutics (NASDAQ:PTGX) Given Outperform Rating at Wedbush - MarketBeat
Analysts Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Price Target at $52.83 - Defense World
State of Alaska Department of Revenue Takes Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
28,500 Shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Acquired by Louisiana State Employees Retirement System - MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) shareholders are still up 353% over 5 years despite pulling back 3.0% in the past week - Simply Wall St
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Allspring Global Investments Holdings LLC Increases Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Allspring Global Investments Holdings LLC Buys 103,414 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics stock hits 52-week high at $48.34 By Investing.com - Investing.com South Africa
Protagonist Therapeutics (NASDAQ:PTGX) Sets New 52-Week HighHere's What Happened - MarketBeat
Protagonist Therapeutics stock hits 52-week high at $48.34 - Investing.com India
Cavalier Investments LLC Purchases New Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Short Interest Update - MarketBeat
Cwm LLC Increases Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Moody Aldrich Partners LLC Sells 14,928 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Bleakley Financial Group LLC Takes Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
(PTGX) Investment Report - Stock Traders Daily
Swedbank AB Purchases New Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics Inc. (PTGX): Advancing Treatments for Autoimmune Diseases - Insider Monkey
State Street Corp's Strategic Acquisition in Protagonist Therapeutics Inc - Yahoo Finance
State Street Corp's Strategic Acquisition in Protagonist Therape - GuruFocus.com
The Prognosis For Protagonist Therapeutics: Solid Prospects, But Stock Is Pricey (PTGX) - Seeking Alpha
Polycythemia Vera Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Clinical Trials | Roche, Fujifilm Holdings Corp, Hangzhou Bensheng Pharma, Protagonist Therapeutics, Ascentage - The Globe and Mail
Is Protagonist Therapeutics Inc (PTGX) positioned for future growth? - SETE News
Protagonist Therapeutics stock hits 52-week high at $48.01 By Investing.com - Investing.com UK
Protagonist Therapeutics (PTGX) is on the Move, Here's Why the Trend Could be Sustainable - Yahoo Canada Finance
Protagonist Therapeutics stock hits 52-week high at $48.01 - Investing.com India
Protagonist Therapeutics Inc [PTGX] Chief Financial Officer makes an insider sale of 14,203 shares worth $0.63 million. - Knox Daily
Inspire Investing LLC Acquires 26,280 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
When (PTGX) Moves Investors should Listen - Stock Traders Daily
AQR Capital Management LLC Sells 55,952 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Cubist Systematic Strategies LLC Has $2.92 Million Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
It makes sense and dollars to buy Protagonist Therapeutics Inc (PTGX) stock - SETE News
SG Americas Securities LLC Grows Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
A company insider recently sold 14,203 shares of Protagonist Therapeutics Inc [PTGX]. Should You Sale? - Knox Daily
Market Watch: Protagonist Therapeutics Inc (PTGX)’s Noteworthy Gain, Closing at 44.18 - The Dwinnex
A closer look at Protagonist Therapeutics Inc (PTGX) is warranted - US Post News
The Manufacturers Life Insurance Company Increases Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives $49.86 Average PT from Analysts - MarketBeat
Hsbc Holdings PLC Has $257,000 Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Dimensional Fund Advisors LP Sells 175,172 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
157,788 Shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Acquired by Northwestern Mutual Wealth Management Co. - MarketBeat
Northwestern Mutual Wealth Management Co. Acquires New Shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Market Momentum: Protagonist Therapeutics Inc (PTGX) Registers a -1.40 Decrease, Closing at 44.37 - The Dwinnex
(PTGX) Trading Report - Stock Traders Daily
4,415 Shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Bought by Point72 DIFC Ltd - Defense World
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by American Century Companies Inc. - Defense World
Protagonist Therapeutics Inc (PTGX) 財務データ
収益
当期純利益
現金流量
EPS
Protagonist Therapeutics Inc (PTGX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Ali Asif | Chief Financial Officer |
Sep 11 '24 |
Sale |
44.49 |
14,203 |
631,872 |
34,960 |
| Waddill William D. | Director |
Sep 10 '24 |
Option Exercise |
12.88 |
8,000 |
103,040 |
20,000 |
| Waddill William D. | Director |
Sep 10 '24 |
Sale |
45.00 |
8,000 |
360,000 |
12,000 |
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):